UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Last trade$28.74
Day change+$0.64 (+2.28%)
Day range$27.19 – $29.29
Volume1,926,799
Market cap$1.38B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.38B
Price / earnings
—
Price / book
-11.01×
Price / sales
5.51×
EV / sales
5.94×
EV / EBITDA
-48.52×
Profitability
Earnings per share
-$1.34
Return on assets
-24.18%
Return on equity
52.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.54×
Current ratio
3.4×
Quick ratio
3.06×
Cash ratio
1.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$132.05M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for URGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$89M
$72.46M
$50.96M
$37.84M
$27.48M
$24.22M
$20.25M
$24.57M
Cost of revenue
$7.5M
$6.57M
$4.14M
$3.29M
$3.28M
$3.55M
$2.33M
$2.47M
Gross profit
$81.5M
$65.88M
$46.82M
$34.55M
$24.2M
$20.67M
$17.92M
$22.09M
Selling, general and administrative
$47.21M
$48.44M
$51.49M
$39.35M
$37.58M
$43.2M
$34.97M
$34.86M
Research and development
$25.96M
$17.34M
$15.6M
$14.31M
$14.01M
$18.91M
$19.87M
$14.89M
Total operating expenses
$73.17M
$65.77M
$67.08M
$53.66M
$51.59M
$62.11M
$54.84M
$49.75M
Operating income
$8.33M
$111K
-$20.26M
-$19.12M
-$27.39M
-$41.45M
-$36.91M
-$27.66M
Interest expense
-$4.84M
-$4.89M
-$4.19M
-$3.77M
-$3.37M
-$4.13M
-$4.07M
-$3.89M
Income before taxes
-$446K
-$8.72M
-$28.35M
-$26.64M
-$34.4M
-$48.93M
-$43.45M
-$34.86M
Income taxes
$1.02M
$5.63M
-$4.77M
-$275K
-$1.05M
$1.02M
$392K
$2.65M
Net income
-$1.46M
-$14.35M
-$23.57M
-$26.36M
-$33.35M
-$49.94M
-$43.84M
-$37.51M
Net income attributable to common shareholders
-$1.46M
-$14.35M
-$23.57M
-$26.36M
-$33.35M
-$49.94M
-$43.84M
-$37.51M
EBITDA
$8.41M
$189K
-$20.19M
-$19.04M
-$27.31M
-$41.37M
-$36.84M
-$27.59M
Basic earnings per share
-$0.03
-$0.28
-$0.47
-$0.54
-$0.69
-$1.05
-$0.92
-$0.80
Diluted earnings per share
-$0.03
-$0.28
-$0.47
-$0.54
-$0.69
-$1.05
-$0.92
-$0.80
Recent news
Company coverage with links to the original publishers.
Urogen Pharma reported a quarterly loss of $0.03 per share, beating the consensus estimate of $0.05, with revenues of $89 million exceeding expectations by 2.73%. Despite the positive earnings surprise and 46.9% year-to-date stock gain, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release, suggesting near-term underperformance relative to the market.
UroGen Pharma announced the first patient dosing in a Phase 1 clinical trial of UGN-501, an investigational next-generation oncolytic virus designed to treat non-muscle invasive bladder cancer (NMIBC). The open-label, dose-escalation trial will evaluate safety, tolerability, and pharmacokinetics of intravesical administration in patients with recurrent NMIBC. The company is also conducting parallel nonclinical studies exploring UGN-501 formulation with its proprietary RTGel technology.
UroGen Pharma Ltd. announced it will report third quarter 2026 financial results on November 4th, 2026, followed by a live audio webcast and conference call at 10:00 AM Eastern Time. The biotech company is dedicated to developing innovative treatments for urothelial and specialty cancers using its proprietary RTGel® reverse-thermal hydrogel platform technology.
UroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.
Zacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.